摘要
目的探讨晚期非小细胞肺癌患者的切除修复交叉互补基因ERCC1基因多态性与表达情况与多西他赛+顺铂(TP)化疗方案疗效关系。方法分别用测序和免疫组织化学法检测100例晚期非小细胞肺癌患者的ERCC1基因C8092A位点和C118T位点基因型,同时利用免疫组织化学法检测ERCC1基因在肿瘤组织中表达情况,并分析与TP的化疗疗效关系。结果 ERCC1的两个位点的基因型多态性均与顺铂疗效之间差异无统计学意义(P>0.05);对两个位点组合分析,同为CC基因型患者疗效的有效率高于非同为CC基因型患者,但差异无统计学意义(P>0.05);Kaplan-Meier生存曲线分析两位点基因多态性与无进展生存期(PFS)关系,C8092A位点的CC、CA+AA基因型的中位PFS分别为4.9月、4.3月,差异有统计学意义(P<0.05);C118T的CC、CT+TT基因型的中位PFS分别为4.4月、4.6月,差异无统计学意义(P>0.05);免疫组织化学结果显示ERCC1表达阴性患者中TP疗效总有效率(48.6%)显著高于阳性患者(23.3%),差异有统计学意义(P<0.05)。ERCC1阴性患者中位PFS(5.0月)显著高于阳性患者(3.8月),差异有统计学意义(P<0.01)。结论 ERCC1基因C8092A和C118T基因多态性TP疗效之间无显著性关系,C8092A位点CC基因型的患者有较长的PFS;ERCC1的表达情况可以作为晚期非小细胞肺癌的TP化疗方案的预后因素之一。
Objective To research the correlation of the gene polymorphism,expression level of excision repair cross complementation group 1 （ERCC1） and curative effect in patients with advanced non-small cell lung cancer （NSCLC） patients treated with platinum-based （TP） chemotherapy.Methods Sequencing was used for detecting the single nucleotide polymorphism （SNP） loci C8092A and C118T of ERCC1 in 100 patients with NSCLC,and immunohistochemical method （IHC） was used for detecting the expression of ERCC1 in tumor tissue.And the relationship of effect of chemotherapy and TP was analyzed.Results There were no correlation between polymorphism of C8092A,C118T and TP curative effect in patients with advanced NSCLC.Comprehensive analysis with two loci together found that there was better curative effect in both CC genotypes.However,the difference was not statistically significant.Progression free survival （PFS） of genotype CC and CA plus AA in C8092A loci were 4.9 months and 4.3 months,and there was significant difference between two groups （P〈0.05）.PFS of genotype CC and CT plus TT of C118T loci were 4.4 months and 4.6 months,but the difference was not statistically significant （P〉0.05）.The curative effect rate of patients with ERCC1 negative expression was 48.6%,and which of the ERCC1 positive expression was 23.3%,the difference was statistically （P〈0.05）.And PFS of patients with ERCC1 negative expression （5 months） patients was significantly higher than that of the patients with ERCC1 positive expression （3.8 months） （P〈0.01）.Conclusion There is no correlation between the genotype of ERCC1 C8092A or C118T loci and the curative effect of TP in patients with advanced NSCLC.Patients with genotype CC of C8092A loci have a longer PFS than other genotypes.Expression of ERCC1 can be used for one of prognostic factors in the advanced NSCLC patients treated with TP.
出处
《检验医学与临床》
CAS
2017年第9期1233-1235,共3页
Laboratory Medicine and Clinic
基金
武汉市临床医学科研项目(WX14C28)
关键词
晚期非小细胞肺癌
切除修复交叉互补基因
单核苷酸多态性
疗效评价
advanced non-small cell lung cancer
excision repair cross-complementing
single-nucleotide polymorphism
curative effect
